College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} : Fees 2026, Course Duration, Dates, Eligibility
College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} is offered as 3 Years Full Time program, with total intake of 10 seats. The minimum eligibility criteria for B.Pharma {Lateral} is D.Pharm with 45% + OJEE. The total fees for College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} in 2020 is ₹ 2.1 Lakhs for the complete course duration, which includes total tuition fees of ₹ 2.1 Lakhs.
College of Pharmaceutical Sciences Mohuda Ganjam offers a total of 10 seats for B.Pharma {Lateral} .
College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} Fees 2025
College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} Fee has not been released yet. For reference you can check the previous year academic fees in the section below.
College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} Previous Fees
| Fees (2020 - 2021) | Year 1 (in INR) | Year 2 (in INR) | Year 3 (in INR) |
|---|---|---|---|
| Tuition Fees | ₹70000 | ₹70000 | ₹70000 |
| Yearly Fees | ₹70000 | ₹70000 | ₹70000 |
* Fees is refundable
College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} Admission 2025
The minimum eligibility for admission to B.Pharma {Lateral} at College of Pharmaceutical Sciences Mohuda Ganjam is D.Pharm with 45% + OJEE.
Also Check:
| Course Highlights | Details |
|---|---|
| duration | 3 Years (Full Time) |
| course level | UG (Degree) |
| mode of study | On Campus |
| total fees | ₹ 2.4 Lakhs |
| eligibility | Diploma with 45% + OJEE |
Table of Contents
College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} Fees
| Fee Type | Total Amount (INR) |
|---|---|
| tuition fee | ₹2.4 Lakhs |
| total academic fee | ₹2.4 Lakhs |
| hostel fee | ₹1.35 Lakhs |
| total fee | ₹3.75 Lakhs |
College of Pharmaceutical Sciences Mohuda Ganjam B.Pharma {Lateral} Admission Process
Course Finder
Search from 20K+ Courses and 35+ Streams
Popular Streams:
SUBSCRIBE TO OUR NEWS LETTER
Comments